The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for game-changing treatments and impressive returns is undeniable, the linked risks are also considerable. Many o